Immunoinformatics and Molecular Docking Studies Predicted Potential Multiepitope-Based Peptide Vaccine and Novel Compounds against Novel SARS-CoV-2 through Virtual Screening.
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2021
2021
Historique:
received:
14
04
2020
revised:
13
08
2020
accepted:
08
02
2021
entrez:
17
3
2021
pubmed:
18
3
2021
medline:
31
3
2021
Statut:
epublish
Résumé
Coronaviruses (CoVs) are enveloped positive-strand RNA viruses which have club-like spikes at the surface with a unique replication process. Coronaviruses are categorized as major pathogenic viruses causing a variety of diseases in birds and mammals including humans (lethal respiratory dysfunctions). Nowadays, a new strain of coronaviruses is identified and named as SARS-CoV-2. Multiple cases of SARS-CoV-2 attacks are being reported all over the world. SARS-CoV-2 showed high death rate; however, no specific treatment is available against SARS-CoV-2. In the current study, immunoinformatics approaches were employed to predict the antigenic epitopes against SARS-CoV-2 for the development of the coronavirus vaccine. Cytotoxic T-lymphocyte and B-cell epitopes were predicted for SARS-CoV-2 coronavirus protein. Multiple sequence alignment of three genomes (SARS-CoV, MERS-CoV, and SARS-CoV-2) was used to conserved binding domain analysis. The docking complexes of 4 CTL epitopes with antigenic sites were analyzed followed by binding affinity and binding interaction analyses of top-ranked predicted peptides with MHC-I HLA molecule. The molecular docking (Food and Drug Regulatory Authority library) was performed, and four compounds exhibiting least binding energy were identified. The designed epitopes lead to the molecular docking against MHC-I, and interactional analyses of the selected docked complexes were investigated. In conclusion, four CTL epitopes (GTDLEGNFY, TVNVLAWLY, GSVGFNIDY, and QTFSVLACY) and four FDA-scrutinized compounds exhibited potential targets as peptide vaccines and potential biomolecules against deadly SARS-CoV-2, respectively. A multiepitope vaccine was also designed from different epitopes of coronavirus proteins joined by linkers and led by an adjuvant. Our investigations predicted epitopes and the reported molecules that may have the potential to inhibit the SARS-CoV-2 virus. These findings can be a step towards the development of a peptide-based vaccine or natural compound drug target against SARS-CoV-2.
Sections du résumé
BACKGROUND
BACKGROUND
Coronaviruses (CoVs) are enveloped positive-strand RNA viruses which have club-like spikes at the surface with a unique replication process. Coronaviruses are categorized as major pathogenic viruses causing a variety of diseases in birds and mammals including humans (lethal respiratory dysfunctions). Nowadays, a new strain of coronaviruses is identified and named as SARS-CoV-2. Multiple cases of SARS-CoV-2 attacks are being reported all over the world. SARS-CoV-2 showed high death rate; however, no specific treatment is available against SARS-CoV-2.
METHODS
METHODS
In the current study, immunoinformatics approaches were employed to predict the antigenic epitopes against SARS-CoV-2 for the development of the coronavirus vaccine. Cytotoxic T-lymphocyte and B-cell epitopes were predicted for SARS-CoV-2 coronavirus protein. Multiple sequence alignment of three genomes (SARS-CoV, MERS-CoV, and SARS-CoV-2) was used to conserved binding domain analysis.
RESULTS
RESULTS
The docking complexes of 4 CTL epitopes with antigenic sites were analyzed followed by binding affinity and binding interaction analyses of top-ranked predicted peptides with MHC-I HLA molecule. The molecular docking (Food and Drug Regulatory Authority library) was performed, and four compounds exhibiting least binding energy were identified. The designed epitopes lead to the molecular docking against MHC-I, and interactional analyses of the selected docked complexes were investigated. In conclusion, four CTL epitopes (GTDLEGNFY, TVNVLAWLY, GSVGFNIDY, and QTFSVLACY) and four FDA-scrutinized compounds exhibited potential targets as peptide vaccines and potential biomolecules against deadly SARS-CoV-2, respectively. A multiepitope vaccine was also designed from different epitopes of coronavirus proteins joined by linkers and led by an adjuvant.
CONCLUSION
CONCLUSIONS
Our investigations predicted epitopes and the reported molecules that may have the potential to inhibit the SARS-CoV-2 virus. These findings can be a step towards the development of a peptide-based vaccine or natural compound drug target against SARS-CoV-2.
Identifiants
pubmed: 33728324
doi: 10.1155/2021/1596834
pmc: PMC7910514
doi:
Substances chimiques
COVID-19 Vaccines
0
Epitopes, B-Lymphocyte
0
Epitopes, T-Lymphocyte
0
Vaccines, Subunit
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1596834Informations de copyright
Copyright © 2021 Muhammad Waqas et al.
Déclaration de conflit d'intérêts
Authors have no conflicts of interest form anyone.
Références
Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):3048-53
pubmed: 26976607
Nucleic Acids Res. 2019 Jan 8;47(D1):D339-D343
pubmed: 30357391
Daru. 2012 Oct 04;20(1):46
pubmed: 23351328
Front Immunol. 2018 Apr 18;9:826
pubmed: 29720983
PLoS One. 2010 Sep 14;5(9):e12697
pubmed: 20856867
Curr Opin Virol. 2017 Apr;23:1-7
pubmed: 28214731
J Biomol Struct Dyn. 2021 May;39(8):2857-2872
pubmed: 32295479
Theor Biol Med Model. 2013 Jan 04;10:3
pubmed: 23286827
Perspect Biol Med. 1995 Summer;38(4):624-39
pubmed: 7659492
Immunology. 2016 Dec;149(4):386-399
pubmed: 27485738
Euro Surveill. 2020 Feb;25(5):
pubmed: 32019636
Virology. 2018 Apr;517:98-107
pubmed: 29277291
Annu Rev Med. 2017 Jan 14;68:387-399
pubmed: 27576010
Drug Des Devel Ther. 2014 Aug 21;8:1139-49
pubmed: 25187696
Methods Mol Biol. 2015;1263:243-50
pubmed: 25618350
Proc Natl Acad Sci U S A. 2009 Jan 13;106(2):582-7
pubmed: 19124777
J Med Virol. 2020 Feb;92(2):149-160
pubmed: 31517388
Microb Pathog. 2020 Aug;145:104236
pubmed: 32376359
Adv Immunol. 2012;114:177-201
pubmed: 22449782
Curr Top Microbiol Immunol. 2018;419:1-42
pubmed: 28643204
Proteins. 2007 Nov 1;69(2):394-408
pubmed: 17600832
J Mol Biol. 2003 Aug 29;331(5):991-1004
pubmed: 12927536
Bioinformatics. 2004 Nov 22;20(17):3236-7
pubmed: 15044231
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Virus Res. 2015 Dec 2;210:54-61
pubmed: 26200955
Nucleic Acids Res. 2020 Jan 8;48(D1):D84-D86
pubmed: 31665464
J Biomol NMR. 2013 May;56(1):51-63
pubmed: 23625455
Cell Host Microbe. 2012 Jun 14;11(6):607-16
pubmed: 22704621
Nucleic Acids Res. 2011 Jan;39(Database issue):D1164-70
pubmed: 21030437
J Chem Inf Model. 2010 Jun 28;50(6):1034-41
pubmed: 20578727
Lancet. 2003 May 24;361(9371):1767-72
pubmed: 12781535
J Chem Inf Model. 2014 Mar 24;54(3):826-36
pubmed: 24521147
J Med Virol. 2020 Apr;92(4):401-402
pubmed: 31950516
J Med Virol. 2020 Apr;92(4):433-440
pubmed: 31967321
IEEE Int Conf Comput Adv Bio Med Sci. 2011 Feb;2011:13-18
pubmed: 27818847
Curr Infect Dis Rep. 2010 Jan;12(1):4-12
pubmed: 21308494
Comput Biol Chem. 2017 Aug;69:120-125
pubmed: 28666141
Nucleic Acids Res. 2019 Jan 8;47(D1):D464-D474
pubmed: 30357411
Virol Sin. 2018 Feb;33(1):104-107
pubmed: 29500691
J Biol Chem. 2019 Sep 13;294(37):13606-13618
pubmed: 31350335
Nucleic Acids Res. 2006 Jan 1;34(Database issue):D187-91
pubmed: 16381842
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992388
Bioinformatics. 2005 Apr 1;21(7):1028-36
pubmed: 15546935
Viruses. 2020 Jan 24;12(2):
pubmed: 31991541
Nucleic Acids Res. 2016 Jul 8;44(W1):W449-54
pubmed: 27131374
Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19944-9
pubmed: 19036930
Am J Public Health. 2019 Sep;109(9):1288-1293
pubmed: 31318592
Brain Pathol. 2001 Jan;11(1):92-106
pubmed: 11145206
J Transl Med. 2019 Nov 8;17(1):362
pubmed: 31703698
Nucleic Acids Res. 2000 Jan 1;28(1):181-4
pubmed: 10592220
Front Mol Biosci. 2020 Oct 15;7:227
pubmed: 33195402
Lancet Infect Dis. 2013 Sep;13(9):752-61
pubmed: 23891402
Int J Biol Sci. 2010 Nov 03;6(7):675-81
pubmed: 21060729
Biomed Res Int. 2017;2017:5925714
pubmed: 28197415
Nat Struct Mol Biol. 2006 Aug;13(8):751-2
pubmed: 16845391
Curr Top Med Chem. 2008;8(18):1555-72
pubmed: 19075767
Trends Biotechnol. 2011 May;29(5):231-9
pubmed: 21316780
J Chem Inf Model. 2005 Jan-Feb;45(1):177-82
pubmed: 15667143
J Comput Chem. 2010 Jan 30;31(2):455-61
pubmed: 19499576
mBio. 2010 Oct 12;1(4):
pubmed: 21063474
Genome Res. 2004 Jun;14(6):1188-90
pubmed: 15173120
J Virol. 1985 Sep;55(3):836-9
pubmed: 2991600
J Clin Microbiol. 2000 Dec;38(12):4523-6
pubmed: 11101590
Lancet. 2004 May 22;363(9422):1699-700
pubmed: 15158632
J Virol. 2007 Feb;81(3):1274-87
pubmed: 17093194
Protein Sci. 2018 Jan;27(1):135-145
pubmed: 28884485
Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14040-5
pubmed: 16169905
Int J Med Sci. 2017 Oct 15;14(13):1342-1359
pubmed: 29200948
Curr Protoc Bioinformatics. 2014 Dec 12;48:3.13.1-3.13.16
pubmed: 25501942
Bioinformatics. 2014 Mar 15;30(6):846-51
pubmed: 24167156
Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W229-32
pubmed: 18424796
J Med Virol. 2020 Jun;92(6):618-631
pubmed: 32108359
Methods Mol Biol. 1999;112:531-52
pubmed: 10027275
J Chem Biol. 2017 Apr 4;10(3):91-104
pubmed: 28684996
Toxins (Basel). 2013 Jun 21;5(6):1202-18
pubmed: 23793075
J Mol Biol. 1997 Jun 13;269(3):423-39
pubmed: 9199410
Protein Eng. 1995 Feb;8(2):127-34
pubmed: 7630882
Sci Rep. 2016 Dec 09;6:37313
pubmed: 27934901
Nature. 2003 Oct 30;425(6961):915
pubmed: 14586458
J Theor Biol. 2018 Dec 14;459:162-170
pubmed: 30291844
J Immunol. 2006 Jun 15;176(12):7335-45
pubmed: 16751377
R Soc Open Sci. 2019 Jul 31;6(7):190907
pubmed: 31417766
Virol J. 2015 Dec 09;12:211
pubmed: 26646953
J Biomol Struct Dyn. 2020 Oct;38(16):4850-4867
pubmed: 31709929
N Engl J Med. 2014 Jun 26;370(26):2499-505
pubmed: 24896817
Nucleic Acids Res. 2020 Feb 20;48(3):1599
pubmed: 31863579
Biomed Res Int. 2020 May 11;2020:2683286
pubmed: 32461973
Proteins. 2011;79 Suppl 10:161-71
pubmed: 21987485
J Virol. 2018 Aug 16;92(17):
pubmed: 29950425
Nucleic Acids Res. 2005 Apr 22;33(7):2302-9
pubmed: 15849316
Biochemistry. 1986 Sep 23;25(19):5425-32
pubmed: 2430611
Nucleic Acids Res. 2019 Jan 8;47(D1):D94-D99
pubmed: 30365038
Curr Top Med Chem. 2019;19(7):534-554
pubmed: 30836920
Clin Chem. 2020 Apr 1;66(4):549-555
pubmed: 32031583
J Biomed Sci. 2006 Jan;13(1):59-72
pubmed: 16228284
Life Sci. 2019 Jan 15;217:176-184
pubmed: 30528183
Proteins. 2007 Oct 1;69(1):139-59
pubmed: 17598144
Immunol Rev. 2011 Jan;239(1):178-96
pubmed: 21198672
Nature. 2020 Oct;586(7827):113-119
pubmed: 32707573
Drug Discov Today. 2007 May;12(9-10):389-95
pubmed: 17467575
BMC Bioinformatics. 2008 Dec 02;9:514
pubmed: 19055730
Curr Protein Pept Sci. 2009 Jun;10(3):286-96
pubmed: 19519456
J Immunol. 2002 Mar 1;168(5):2371-82
pubmed: 11859128